146 related articles for article (PubMed ID: 30267834)
1. Conformational polymorphic changes in the crystal structure of the chiral antiparasitic drug praziquantel and interactions with calcium carbonate.
Borrego-Sánchez A; Carazo E; Albertini B; Passerini N; Perissutti B; Cerezo P; Viseras C; Hernández-Laguna A; Aguzzi C; Sainz-Díaz CI
Eur J Pharm Biopharm; 2018 Nov; 132():180-191. PubMed ID: 30267834
[TBL] [Abstract][Full Text] [Related]
2. Molecular modeling and infrared and Raman spectroscopy of the crystal structure of the chiral antiparasitic drug Praziquantel.
Borrego-Sánchez A; Hernández-Laguna A; Sainz-Díaz CI
J Mol Model; 2017 Apr; 23(4):106. PubMed ID: 28275906
[TBL] [Abstract][Full Text] [Related]
3. Unexpected solvent impact in the crystallinity of praziquantel/poly(vinylpyrrolidone) formulations. A solubility, DSC and solid-state NMR study.
Costa ED; Priotti J; Orlandi S; Leonardi D; Lamas MC; Nunes TG; Diogo HP; Salomon CJ; Ferreira MJ
Int J Pharm; 2016 Sep; 511(2):983-93. PubMed ID: 27506511
[TBL] [Abstract][Full Text] [Related]
4. Preparation and characterization of a new solid form of praziquantel, an essential anthelmintic drug. Praziquantel racemic monohydrate.
Salazar-Rojas D; Maggio RM; Kaufman TS
Eur J Pharm Sci; 2020 Apr; 146():105267. PubMed ID: 32061654
[TBL] [Abstract][Full Text] [Related]
5. Investigation of the phase diagrams of chiral praziquantel.
Liu Y; Wang X; Wang JK; Ching CB
Chirality; 2006 May; 18(4):259-64. PubMed ID: 16521119
[TBL] [Abstract][Full Text] [Related]
6. Development of flexible and dispersible oral formulations containing praziquantel for potential schistosomiasis treatment of pre-school age children.
Trastullo R; Dolci LS; Passerini N; Albertini B
Int J Pharm; 2015 Nov; 495(1):536-550. PubMed ID: 26386139
[TBL] [Abstract][Full Text] [Related]
7. Molecular and crystal structure of praziquantel. Spectroscopic properties and crystal polymorphism.
Borrego-Sánchez A; Viseras C; Aguzzi C; Sainz-Díaz CI
Eur J Pharm Sci; 2016 Sep; 92():266-75. PubMed ID: 27108679
[No Abstract] [Full Text] [Related]
8. Structural Elucidation of Poloxamer 237 and Poloxamer 237/Praziquantel Solid Dispersions: Impact of Poly(Vinylpyrrolidone) over Drug Recrystallization and Dissolution.
Orlandi S; Priotti J; Diogo HP; Leonardi D; Salomon CJ; Nunes TG
AAPS PharmSciTech; 2018 Apr; 19(3):1274-1286. PubMed ID: 29313262
[TBL] [Abstract][Full Text] [Related]
9. Ground Calcium Carbonate as a Low Cost and Biosafety Excipient for Solubility and Dissolution Improvement of Praziquantel.
Borrego-Sánchez A; Sánchez-Espejo R; Albertini B; Passerini N; Cerezo P; Viseras C; Sainz-Díaz CI
Pharmaceutics; 2019 Oct; 11(10):. PubMed ID: 31615087
[TBL] [Abstract][Full Text] [Related]
10. Exploring mechanochemical parameters using a DoE approach: Crystal structure solution from synchrotron XRPD and characterization of a new praziquantel polymorph.
Zanolla D; Perissutti B; Vioglio PC; Chierotti MR; Gigli L; Demitri N; Passerini N; Albertini B; Franceschinis E; Keiser J; Voinovich D
Eur J Pharm Sci; 2019 Dec; 140():105084. PubMed ID: 31626966
[TBL] [Abstract][Full Text] [Related]
11. [Study on solid dispersion of precipitated calcium carbonate-based oleanolic acid].
Yan HM; Zhang ZH; Jia XB; Jiang YR; Sun E
Zhongguo Zhong Yao Za Zhi; 2015 May; 40(10):1935-8. PubMed ID: 26390651
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo evaluation of praziquantel loaded implants based on PEG/PCL blends.
Cheng L; Lei L; Guo S
Int J Pharm; 2010 Mar; 387(1-2):129-38. PubMed ID: 20005928
[TBL] [Abstract][Full Text] [Related]
13. Transdermal evaporation delivery system of praziquantel for schistosomiasis japonicum chemotherapy.
Wang L; Zheng X; Fang Y; Wang Y; Duan C; Yao B
J Pharm Sci; 2011 Jul; 100(7):2769-77. PubMed ID: 21319162
[TBL] [Abstract][Full Text] [Related]
14. Drug loading into porous calcium carbonate microparticles by solvent evaporation.
Preisig D; Haid D; Varum FJ; Bravo R; Alles R; Huwyler J; Puchkov M
Eur J Pharm Biopharm; 2014 Aug; 87(3):548-58. PubMed ID: 24568926
[TBL] [Abstract][Full Text] [Related]
15. [Progress of research on preparation and application of praziquantel].
Wu DZ; Ma Z; Liu YF; Zhu WF; Ning A
Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi; 2013 Apr; 25(2):194-6. PubMed ID: 23894845
[TBL] [Abstract][Full Text] [Related]
16. A new soluble and bioactive polymorph of praziquantel.
Zanolla D; Perissutti B; Passerini N; Chierotti MR; Hasa D; Voinovich D; Gigli L; Demitri N; Geremia S; Keiser J; Cerreia Vioglio P; Albertini B
Eur J Pharm Biopharm; 2018 Jun; 127():19-28. PubMed ID: 29409939
[TBL] [Abstract][Full Text] [Related]
17. Structural characterization and enantioseparation of the chiral compound praziquantel.
Liu Y; Wang X; Wang JK; Ching CB
J Pharm Sci; 2004 Dec; 93(12):3039-46. PubMed ID: 15514924
[TBL] [Abstract][Full Text] [Related]
18. Resolution of praziquantel.
Woelfle M; Seerden JP; de Gooijer J; Pouwer K; Olliaro P; Todd MH
PLoS Negl Trop Dis; 2011 Sep; 5(9):e1260. PubMed ID: 21949890
[TBL] [Abstract][Full Text] [Related]
19. Compaction of functionalized calcium carbonate, a porous and crystalline microparticulate material with a lamellar surface.
Stirnimann T; Atria S; Schoelkopf J; Gane PA; Alles R; Huwyler J; Puchkov M
Int J Pharm; 2014 May; 466(1-2):266-75. PubMed ID: 24631309
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of calcium carbonate using extract components of croaker gill as morphology and polymorph adjust control agent.
Chen H; Qing C; Zheng J; Liu Y; Wu G
Mater Sci Eng C Mater Biol Appl; 2016 Jun; 63():485-8. PubMed ID: 27040242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
